# Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion

> **NCT05992220** · PHASE2 · RECRUITING · sponsor: **Asan Medical Center** · enrollment: 138 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Hepatocellular Cancer
- Hepatocellular Carcinoma Non-resectable
- Hepatocellular Carcinoma Stage IV
- Liver Cancer

## Interventions

- **RADIATION:** Atezolizumab plus bevacizumab, combined EBRT to vascular invasion
- **DRUG:** Atezolizumab plus bevacizumab

## Key facts

- **NCT ID:** NCT05992220
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-22
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2025-02-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05992220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05992220, "Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05992220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*